Literature DB >> 33140401

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy.

Oumarou Ouédraogo1,2, Rose-Marie Rébillard1,3, Hélène Jamann1,3, Victoria Hannah Mamane1,3, Marie-Laure Clénet1,2, Audrey Daigneault1, Boaz Lahav4, Timo Uphaus5, Falk Steffen5, Stefan Bittner5, Frauke Zipp5, Arline Bérubé3,4, Samuel Lapalme-Remis3,4, Patrick Cossette1,3,4, Dang Khoa Nguyen1,3,4, Nathalie Arbour1,3, Mark R Keezer1,3,4,6, Catherine Larochelle1,3,4.   

Abstract

OBJECTIVE: Adult drug-resistant epilepsy (DRE) is associated with significant morbidity. Infiltration of immune cells is observed in DRE epileptic foci; however, the relation between DRE and the peripheral immune cell compartment remains only partially understood. We aimed to investigate differences in immune cell populations, cytokines, and neurodegenerative biomarkers in the peripheral blood of subjects with epilepsy versus healthy controls, and in DRE compared to well-controlled epilepsy (WCE).
METHODS: Peripheral blood mononuclear cells and serum from >120 age- and sex-matched adults suffering from focal onset epilepsy and controls were analyzed by multipanel flow cytometry, multiplex immunoassays, and ultrasensitive single molecule array.
RESULTS: Using a data-driven analytical approach, we identified that CD4 T cells in the peripheral blood are present in a higher proportion in DRE patients. Moreover, we observed that the frequency of CD4 T cells expressing proinflammatory cytokines interleukin (IL)-17A, IL-22, tumor necrosis factor, interferon-γ, and granulocyte-macrophage colony-stimulating factor, but not anti-inflammatory cytokines IL-10 and IL-4, is elevated in the peripheral blood of DRE subjects compared to WCE. In parallel, we found that Th17-related circulating proinflammatory cytokines are elevated, but Th2-related cytokine IL-4 is reduced, in the serum of epilepsy and DRE subjects. As Th17 cells can exert neurotoxicity, we measured levels of serum neurofilament light chain (sNfL), a marker of neuronal injury. We found significantly elevated levels of sNfL in DRE compared to controls, especially among older individuals. SIGNIFICANCE: Our data support that DRE is associated with an expansion of the CD4 Tcell subset in the peripheral blood and with a shift toward a proinflammatory Th17/Th1 CD4 Tcell immune profile. Our results further show that pathological levels of sNfL are more frequent in DRE, supporting a potential neurodegenerative component in adult DRE. With this work, we provide evidence for novel potential inflammatory and degenerative biomarkers in DRE.
© 2020 International League Against Epilepsy.

Entities:  

Keywords:  CD4 T cells; drug-resistant epilepsy; inflammatory cytokines; serum neurofilament light chain (sNfL)

Mesh:

Substances:

Year:  2020        PMID: 33140401     DOI: 10.1111/epi.16742

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus.

Authors:  Giada Giovannini; Roberta Bedin; Diana Ferraro; Anna Elisabetta Vaudano; Jessica Mandrioli; Stefano Meletti
Journal:  Epilepsia       Date:  2021-11-21       Impact factor: 6.740

2.  CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy.

Authors:  Robert Daniel Nass; Katja Akgün; Karmele Olaciregui Dague; Christian Erich Elger; Heinz Reichmann; Tjalf Ziemssen; Rainer Surges
Journal:  Front Neurol       Date:  2021-04-16       Impact factor: 4.003

3.  Neurofilament Light Chain Is a Novel Biomarker for Major Depression and Related Executive Dysfunction.

Authors:  Mu-Hong Chen; Yu-Li Liu; Hsiang-Wei Kuo; Shih-Jen Tsai; Ju-Wei Hsu; Kai-Lin Huang; Pei-Chi Tu; Ya-Mei Bai
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

4.  Characterization of Immune-Related Genes and Immune Infiltration Features in Epilepsy by Multi-Transcriptome Data.

Authors:  Yunqi Hou; Zhen Chen; Liping Wang; Yingxin Deng; Genglong Liu; Yongfen Zhou; Haiqin Shi; Xiangqun Shi; Qianhua Jiang
Journal:  J Inflamm Res       Date:  2022-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.